OR WAIT null SECS
July 19, 2022
TFF Pharmaceuticals is expanding its R&D operations with a new facility in Austin, Texas.
July 12, 2022
Wacker is investing more than €100 million (US$100.5 million) to expand its Halle, Germany, site with an mRNA competence center.
June 13, 2022
REGENXBIO has opened a new in-house facility at its headquarters in Rockville, Md., that will be used to manufacture AAV gene therapies at commercial scale.
June 10, 2022
Astellas Pharma has opened its new gene therapy manufacturing facility in Sanford, NC, which will support clinical- and commercial-scale manufacturing of AAV vectors for gene therapies.
The expansion at Seqirus’ Holly Springs, N.C., manufacturing facility will support the formulation and fill/finish of influenza vaccines.
May 26, 2022
AGC Biologics is investing in viral vector suspension technology at its new Longmont, Colo., facility.
April 28, 2022
Thermo Fisher Scientific has expanded its state-of-the-art R&D facility in Hyderabad, India.
April 22, 2022
Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.
April 18, 2022
High Purity New England has launched its third facility, focused on single-use assemblies.
April 14, 2022
Achilles Therapeutics has announced that it will expand its clinical manufacturing capabilities in the UK and enter a partnership agreement for expansion in the US.